Search

Corvus Pharmaceuticals Inc

Uždarymo kaina

14.88 -1.78

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.62

Max

15.16

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-4.3M

-18M

Pelnas, tenkantis vienai akcijai

-0.19

Darbuotojai

37

EBITDA

-5.3M

-17M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+94.85% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

32M

1.2B

Ankstesnė atidarymo kaina

16.66

Ankstesnė uždarymo kaina

14.88

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-14 23:56; UTC

Columbia Banking System Inc shares are higher in after-market trading, maintaining an upward trend since Friday's close, with no specific news identified for the movement.

2026-08-14 23:56; UTC

Lowe's Companies Inc saw modest gains during after-market hours, trading near the upper end of its one-month range and above its 20-day moving average.

2026-08-14 23:56; UTC

CEVA Inc shares are higher in after-market trading, reaching a session high earlier. The stock remains within its one-month trading range.

2026-08-14 23:56; UTC

Whirlpool Corp shares are trading lower in after-market hours. No specific news was identified to explain the movement.

2026-08-14 23:56; UTC

ETF Constituents

Vanguard FTSE Developed Markets ETF rises in after-market trading, supported by strong performances from top holdings including UL, KB, SAP, FLUT, and CVE.

2026-08-14 23:56; UTC

Ardelyx Inc. shares declined in after-market trading, continuing a broader trend of significant decline over the past month, remaining below the 20-day moving average.

2026-08-14 23:56; UTC

Aptiv PLC shares are trading higher in after-market hours following an early spike, amid a market characterized by complacency and stable equities.

2026-08-14 23:56; UTC

Fox Corp shares are lower in after-market hours, showing unusual volatility. No specific news was identified to explain the movement.

2026-08-14 23:56; UTC

Encore Capital Group Inc shares are higher in after-market trading, continuing a positive trend following four consecutive sessions of gains. No specific news was identified.

2026-08-14 23:56; UTC

Commercial Metals Co. shares declined after-market, continuing a trend of three consecutive lower daily closes, despite remaining above the 20-day moving average.

2026-08-14 23:56; UTC

ETF Constituents

The Consumer Staples Select Sector SPDR Fund is trading higher in after-market hours, supported by gains from top holdings like Monster Beverage and Walmart.

2026-08-14 23:56; UTC

Macro News
ETF Constituents

VanEck Gold Miners ETF rises in after-market trading amid U.S.-Iran tensions and a weaker U.S. Dollar Index, boosting demand for safe-haven assets.

2026-08-14 23:56; UTC

Cognizant Technology Solutions shares are higher in after-market trading, recovering from earlier losses amid a mixed backdrop in global equity markets.

2026-08-14 23:52; UTC

News

Boeing Co secures over $711 million in U.S. defense contract modifications, boosting investor sentiment. Shares are higher in after-market trading.

2026-08-14 23:51; UTC

Insight Enterprises Inc. shares are trading slightly lower after-market, amid broader market concerns following a surprising decline in U.S. retail sales for July.

2026-08-14 23:51; UTC

Turning Point Brands Inc shares are higher in after-market hours, trading above their 20-day moving average amid broader market concerns over declining U.S. retail sales.

2026-08-14 23:51; UTC

ETF Constituents

Energy Select Sector SPDR Fund rose in after-market hours, driven by gains from Valero Energy, Chevron, and Exxon Mobil, offsetting minor declines from Marathon and Occidental.

2026-08-14 23:51; UTC

Vipshop Holdings Ltd shares are higher in after-market hours, diverging from recent declines despite a drop in U.S. retail sales for July.

2026-08-14 23:51; UTC

Kanzhun Ltd. shares are lower in after-market hours, reflecting a decline following disappointing U.S. retail sales data and shifting market sentiment on interest rates.

2026-08-14 23:51; UTC

Cognex Corp shares are lower in after-market hours amid broader market concerns following a decline in U.S. retail sales for July.

2026-08-14 23:51; UTC

Abercrombie & Fitch Co shares are lower in after-market hours following a decline in U.S. retail sales for July, raising concerns about consumer spending.

2026-08-14 23:51; UTC

RingCentral Inc. shares are higher in after-market trading, reflecting positive momentum following Friday's close, despite concerns over July's U.S. retail sales decline.

2026-08-14 23:51; UTC

Social Media

Moderna shares are lower in after-market hours amid concerns over the FDA's approval of its mRNA flu vaccine and modest trial data effectiveness.

2026-08-14 23:51; UTC

Tower Semiconductor shares are higher in after-market trading, remaining above their 20-day moving average despite a decline in U.S. retail sales for July.

2026-08-14 23:51; UTC

Karyopharm Therapeutics shares are higher in after-market trading, despite no specific news. Broader market sentiment reflects concerns from a decline in U.S. retail sales.

2026-08-14 23:51; UTC

News

PayPal is in advanced talks for a potential sale to Stripe and Advent, following a proposal of $60.50 per share. Shares are higher in after-market trading.

2026-08-14 23:51; UTC

China's House Price Index YoY release on August 17, 2026, signals cautious market sentiment amid ongoing housing challenges and weak demand.

2026-08-14 23:51; UTC

Social Media

BJ's Wholesale Club Holdings Inc. is trading higher in after-market hours following its scheduled earnings report amid positive market sentiment despite a drop in U.S. retail sales.

2026-08-14 23:51; UTC

Griffon Corp shares are lower in after-market hours amid weak market sentiment and disappointing U.S. retail sales data, which diverged from expectations.

2026-08-14 23:51; UTC

In after-market trading, Bloomin' Brands Inc is moving higher, reflecting strong performance despite a decline in U.S. retail sales for July.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

94.85% į viršų

12 mėnesių prognozė

Vidutinis 29.5 USD  94.85%

Aukščiausias 33 USD

Žemiausias 27 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat